Migraine.
Recent advances in migraine therapy include the recognition of analgesic or ergotamine abuse as a cause of chronic daily migraine, the introduction of effective non-narcotic drugs such as chlorpromazine, dihydroergotamine and corticosteroids for the treatment of intractable migraine attacks, the increased number of beta-blockers now recognized as effective prophylactic agents and the introduction of calcium-channel blockers for prophylaxis. There is a sufficient variety of antimigraine drugs, and therapy should be successful for most sufferers.
D000208:Acute Disease; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000700:Analgesics / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002746:Chlorpromazine / Q000627:therapeutic use; D004087:Dihydroergotamine / Q000627:therapeutic use; D004878:Ergotamine / Q000627:therapeutic use; D006801:Humans; D008784:Methysergide / Q000627:therapeutic use; D008881:Migraine Disorders / Q000188:drug therapy* / Q000517:prevention & control; D009294:Narcotics / Q000627:therapeutic use; D010918:Pizotyline / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D000319:Adrenergic beta-Antagonists; D000700:Analgesics; D002121:Calcium Channel Blockers; D009294:Narcotics; D010918:Pizotyline; D004087:Dihydroergotamine; D004878:Ergotamine; D002746:Chlorpromazine; D008784:Methysergide